Pancreatic Cancer Research

ResearcherChinese PLA General HospitalActive in the last 2 years

Yi Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9319-5692; OpenAlex author ID A5042174429. Sources: ClinicalTrials.gov.

Their work

Papers
5 (first author 0, last author 4)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
9
Papers, trials and grants by year

2016: 1 trial · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 5

  1. Dahuang Zhechong Pill Combined with TNS4 Silencing Inhibits the NF-Κb/VEGF Pathway To Slow Down The Progression Of Pancreatic Cancer. Co-author DOI 10.2174/0115748928379439250621171215↗
  2. Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune … Last author DOI 10.3389/fonc.2021.585271↗
  3. Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation. Last author PMID 32194909↗
  4. Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis. Last author DOI 10.3892/mmr.2018.9663↗
  5. Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohort. Last author DOI 10.2147/tcrm.s173041↗

Trials 1

  1. Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer Principal investigator NCT02945267↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haitao Tao · 3 shared papers, 2019–2021 · strength 0.36
  2. Rensong Yue · 1 shared paper, 2026 · strength 0.36
  3. Dawei Yan · 1 shared paper, 2026 · strength 0.36
  4. Junxun Ma · 2 shared papers, 2018–2021 · strength 0.20
  5. Jin Shang · 1 shared paper, 2021 · strength 0.13
  6. Lukuan You · 1 shared paper, 2019 · strength 0.11
  7. Jing Zhang · 1 shared paper, 2019 · strength 0.11
  8. Fan Zhang · 1 shared paper, 2018 · strength 0.08
  9. Danyang Sun · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.